Mitsutaka Nishimoto
Overview
Explore the profile of Mitsutaka Nishimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moriguchi M, Nakamae H, Nishimoto M, Sugita J, Yanada M, Toubai T, et al.
Br J Haematol
. 2024 Oct;
205(6):2376-2386.
PMID: 39439234
HLA-haploidentical haematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is emerging as an effective alternative due to donor availability and safety. We conducted a nationwide retrospective study comparing the outcomes of...
2.
Nishijima M, Ido K, Okayama Y, Okamura H, Kuno M, Makuuchi Y, et al.
Int J Hematol
. 2024 Aug;
120(5):645-650.
PMID: 39210087
Acute lymphoblastic leukemia (ALL) relapsed after allogeneic hematopoietic cell transplantation (allo-HCT) has a catastrophic prognosis. Blinatumomab, a CD3/CD19-directed bispecific T cell engager, is reportedly effective for advanced B-cell ALL (B-ALL),...
3.
Fuji S, Nakamae H, Sugita J, Najima Y, Konishi T, Tanaka T, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1628-1630.
PMID: 39187600
No abstract available.
4.
Nakako S, Okamura H, Yokota I, Umemoto Y, Horiuchi M, Sakatoku K, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1088.e1-1088.e12.
PMID: 39147137
Although various relapse prediction models based on pretransplant information have been reported, they cannot update the predictive probability considering post-transplant patient status. Therefore, these models are not appropriate for deciding...
5.
Nakako S, Koh H, Sogabe N, Kuno M, Makuuchi Y, Takakuwa T, et al.
Transpl Immunol
. 2024 Aug;
86:102107.
PMID: 39142540
The reportedly poor outcome of late-onset idiopathic pneumonia syndrome (IPS) necessitates new approaches to its treatment. A 55-year-old man who had undergone allogeneic hematopoietic cell transplantation (allo-HCT) for myelodysplastic syndrome...
6.
Hayashi T, Nakashima Y, Takeda S, Nishimoto M, Okamura H, Takakuwa T, et al.
Eur J Haematol
. 2024 Jul;
113(5):651-663.
PMID: 39072897
Objectives: Impaired B-cell reconstitution after allogeneic hematopoietic cell transplantation (allo-HCT) contributes to the pathogenesis of chronic graft-versus-host disease (cGVHD). Therefore, methods to consistently achieve effective B cell lymphogenesis are required....
7.
Makuuchi Y, Okamura H, Umemoto Y, Nishikawa A, Tanaka R, Sato A, et al.
Rinsho Ketsueki
. 2024 Jun;
65(5):321-329.
PMID: 38825508
Health surveys to assess adverse events after peripheral blood stem cell harvest (PBSCH) have conventionally been conducted by phone, but phone calls are suboptimal for conducting frequent surveys. We developed...
8.
Nagasaki J, Nishimoto M, Koh H, Okamura H, Nakamae M, Sakatoku K, et al.
Blood Cancer J
. 2024 May;
14(1):79.
PMID: 38744860
No abstract available.
9.
Tazoe K, Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, et al.
Ann Hematol
. 2024 Apr;
103(6):2059-2072.
PMID: 38662207
Myelodysplastic syndrome (MDS) is well known to be complicated by systemic inflammatory autoimmune disease (SIADs). However, it remains unclear how the prognosis after allogenic hematopoietic stem cell transplantation (allo-HSCT) in...
10.
Izutsu K, Kato H, Sekiguchi N, Fujisaki T, Kawakita T, Obara N, et al.
Int J Hematol
. 2024 Apr;
120(1):80-90.
PMID: 38597986
Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received...